ImageDrug maker Aurobindo Pharma said on Monday that its Australian subsidiary has received approval from the government agency for registering its anti-hypertension drug Auro-Linsinopril in that country.

Aurobindo Pharma Australia, the wholly-owned subsidiary of the Indian firm, has received its first approval from the Therapeutic Goods Administration (TGA) of Australia for the registration of Auro-Linsinopril in three variants, the drug major said in a filing to the Bombay Stock Exchange.

The company got approval from TGA for Auro-Linsinopril in the strengths of 5, 10 and 20 mg, it further said.

These therapeutic products are used in the treatment of hypertension, congestive heart failure and acute myocardial infarction.